Exelon

Exelixis is a commercial-stage biotechnology company primarily focused on the discovery, development, and commercialization of small molecule therapies for difficult-to-treat cancers. The company's flagship product, Cabometyx (cabozantinib), is a multi-tyrosine kinase inhibitor approved for various indications including renal cell carcinoma and hepatocellular carcinoma. Beyond its core oncology portfolio, Exelixis is expanding its pipeline through internal research and strategic collaborations, focusing on next-generation targeted therapies and antibody-drug conjugates. The company maintains a robust clinical development program aimed at maximizing the potential of its existing assets while advancing new candidates into the clinic. Exelixis is headquartered in Alameda, California, and continues to be a significant player in the global oncology market.